Volume 12, Number 4—April 2006
Letter
Lack of Transmission of Vaccinia Virus
James H. Stark*, Sharon E. Frey†, Paul S. Blum*, and Thomas P. Monath*
Table
Sampling outcomes of 43 study participants who received 1 of 3 smallpox vaccines
| Variable | All participants (N = 43) | Vaccine group |
||
|---|---|---|---|---|
| ACAM1000 (n = 14) | ACAM2000 (n = 15) | Dryvax (n = 14) | ||
| Mean ± SD titer from lesion*†‡ | ||||
| Day 7 | 3.84 ± 0.98 | 3.77 ± 1.15 | 3.85 ± 1.06 | 3.91 ± 0.74 |
| Day 10 | 3.75 ± 0.89 | 3.62 ± 0.54 | 3.58 ± 1.21 | 4.07 ± 0.74 |
| Day 15 | 4.19 ± 1.40 | 4.08 ± 1.24 | 3.67 ± 1.57 | 4.86 ± 1.18 |
| Mean ± SD titer from dressing§ | ||||
| Day 7 | 0.63 ± 0.85 | 0.9 ± 1.50 | 0 | 0 |
| Day 10 | 0 | 0 | 0 | 0 |
| Day 15 | 0 | 0 | 0 | 0 |
*Viral shedding results reported as <X were converted to X/2 before calculating.
†Titers are reported as log10 PFU/mL.
‡There were no significant differences among the groups (p>0.05).
§Limit of detection was 1.0 log10 PFU/mL.
Page created: January 24, 2012
Page updated: January 24, 2012
Page reviewed: January 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.